| abstract |
1. A method for modulating the function and / or expression of a pancreatic developmental gene polynucleotide in a patient’s cells or tissues in vivo or in vitro, comprising: contacting said cells or tissues with at least one antisense oligonucleotide of 5 to 30 nucleotides in length moreover, the specified at least one oligonucleotide has a sequence of at least 50% identical to the sequence inverse to the polynucleotide containing from 5 to 30 consecutive nucleotides in the range from 1 to 1235 nucleotides of the sequence SEQ ID SEQ ID NO: 6, 1 to 17964 nucleotides of the sequence SEQ ID NO: 7, 1 to 1 to 50003 nucleotides of the sequence SEQ ID SEQ ID NO: 8, 1 to 486 nucleotides of the sequence SEQ ID NO: 9 , from 1 to 494 nucleotides of the sequence SEQ ID NO: 10, from 1 to 1992 the nucleotides of the sequence SEQ ID NO: 11, or from 1 to 1767 nucleotides of the sequence SEQ ID NO: 12; with modulating, therefore, the function and / or expression of the indicated polynucleotide of the pancreatic development gene in the cells or tissues of the patient in vivo or in vitro. 2. A method for modulating the function and / or expression of a pancreatic developmental gene polynucleotide in a patient’s cells or tissues in vivo or in vitro, comprising: contacting said cells or tissues with at least one antisense oligonucleotide of 5-30 nucleotides in length, said at least one oligonucleotide has a sequence that is at least 50% identical to the inverse of the complementary sequence of the natural antisense sequence to the polynucleotide of the pancreatic development gene th gland; with modulation, t� |